Natalizumab biosimilar is under clinical development by Polpharma Biologics and currently in Pre-Registration for Secondary Progressive Multiple Sclerosis (SPMS). According to GlobalData, Pre-Registration drugs for Secondary Progressive Multiple Sclerosis (SPMS) have a 95% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Natalizumab biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Natalizumab biosimilar overview

Natalizumab biosimilar is under development for the treatment of relapsing-remitting multiple sclerosis, secondary progressive multiple sclerosis  and Crohn's disease. The drug candidate acts by targeting alpha4-subunit of alpha4beta1 and alpha4beta7 integrins. The drug candidate is developed using CHO technology platform. 

For a complete picture of Natalizumab biosimilar’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.